VIRGINIA AND DANIEL K. LUDWIG CHAIR IN CANCER RESEARCH
Established in 1996 by the Virginia and D.K. Ludwig Fund for Cancer Research (Inter Vivos)

Image Credit: Virginia and D.K. Ludwig Fund DANIEL K. LUDWIG, who died in 1992, pioneered the development of supertankers and became a major figure on a global scale in shipping; in the production of forest and agricultural products, oil, gas, coal, and other minerals; and in hotels and commercial real estate. In his later years, Mr. Ludwig dedicated virtually all of his fortune to the support of cancer research. A very private man, he made a rare public appearance to accept an honorary degree from Johns Hopkins in 1980. In 1971 he established, and later funded, the Ludwig Institute for Cancer Research. Based in Switzerland, with its scientific direction in New York, the institute carries out research programs around the globe. In addition, Mr. Ludwig provided substantial support for cancer research programs--including the creation of Ludwig Professorships--at six United States academic institutions that he considered to be leaders in the field: Hopkins, Harvard, MIT, Memorial Sloan-Kettering, Stanford, and Chicago Pritzker. The VIRGINIA AND D.K. LUDWIG FUND FOR CANCER RESEARCH (INTER VIVOS), named for Mr. Ludwig and his wife, was established during his lifetime for this purpose. A corresponding charitable trust in their names was established under his will and, jointly, with the Inter Vivos Trust, made a commitment to create a second Ludwig Professorship at Hopkins in 1999, for the support of clinical evaluation and teaching. Together the two Ludwig Chairs at Hopkins are intended to facilitate the transition of discoveries from the laboratory to the clinic in a collaborative academic environment where basic research and clinical investigation are viewed as a continuum.

 

STEPHEN B. BAYLIN, the Virginia and Daniel K. Ludwig Professor of Cancer Research, is internationally recognized as a leader and innovator in fundamental cancer research. Dr. Baylin trained at Hopkins in internal medicine, physiology, and endocrinology, and joined the faculty in 1974. As chief of the Cancer Biology Division of the Oncology Center, Dr. Baylin oversees cancer research projects and conducts his own research into the biology of abnormal epigenetic gene silencing in cancer. He has authored more than 300 articles and book chapters and has made significant discoveries in describing molecular processes involved in the progression of human lung and other epithelial cancers.